Company
Headquarters: Seoul, South Korea
Employees: 2,155
CEO: Mr. Jong-Soo Woo Ph.D.
₩4.505 Trillion
KRW as of Jan. 1, 2024
US$3.48 Billion
| Company | Market Cap (USD) |
|---|---|
| Zoetis Inc. | $89.09 B |
| MERCK Kommanditgesellschaft auf Aktien | $67.64 B |
| Takeda Pharmaceutical Company Limited | $47.71 B |
| Haleon plc | $38.90 B |
| PPD, Inc. | $16.58 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Hanmi Pharm. Co., Ltd. operates as a pharmaceutical company worldwide. It develops treatments for diabetes, obesity, cancer, autoimmune, and rare diseases. The company was founded in 1973 and is based in Seoul, South Korea.
Top 1-year algo backtest: +284.14%
$10,000 in April 2023 would now be $38,414 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Hanmi Pharm. Co. Ltd has the following listings and related stock indices.
Stock: KRX: 128940 wb_incandescent